Wafa is a Venture Scientist at Synapto Ventures, where she supports due diligence, investment evaluation, and strategic fundraising for early-stage life science companies. Her work spans scientific assessment, venture strategy, and commercialisation—bridging research with scalable impact.
She brings cross-functional experience across biopharma, digital health, and go-to-market execution. Prior to Synapto, Wafa led digital healthcare innovation at AstraZeneca Singapore, where she developed a portfolio of solutions across oncology, respiratory, cardiology, and chronic diseases. She explored digital therapeutics, platform solutions, wearables, and telehealth technologies, and established ecosystem partnerships with startups, public healthcare institutions, and government bodies—experiences that shaped her belief in working with like-minded innovators to drive meaningful change.
She also collaborated with GSK on an omni channel launch strategy for a haematology therapy in Northwest Europe, deepening her exposure to market access and commercial planning in complex healthcare systems.
At Synapto, Wafa combines scientific rigor and strategic insight to support founders on their path from lab to market—connecting innovation with capital, guidance, and long-term growth.
Wafa holds a Bachelor in Science in BiologicalSciences (Hons) from Nanyang Technological University (NTU) and a Master in Business Administration (MBA) from INSEAD.
